Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) recently asked the U.S. Patent Office to extend one of its patents on their multiple sclerosis drug, Copaxone. There are several drug companies battling to make a generic version of the profitable medicine, and Teva Pharmaceutical is doing everything it can to protect its proprietary drug. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares after opening at $50.46 moved to $50.87 on last trade day and at the end of the day closed at $50.33. Company price to sales ratio in past twelve months was calculated as 2.37 and price to cash ratio as 46.35. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) showed a negative weekly performance of -5.04%.
Allergan (NYSE:AGN) has earned an average recommendation of “Buy” from the twenty-three ratings firms that are currently covering the company, Analyst Ratings Network reports. Allergan, Inc. (NYSE:AGN) shares advanced 3.65% in last trading session and ended the day on $120.89. AGN return on equity ratio is recorded as 14.70% and its return on assets is 8.80%. Allergan, Inc. (NYSE:AGN) yearly performance is 4.40%.
Amgen, Inc.(NASDAQ:AMGN) announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Amgen, Inc. (NASDAQ:AMGN) shares moved down -1.90% in last trading session and was closed at $111.94 while trading in range of $111.90 – $116.09 – Amgen, Inc. (NASDAQ:AMGN) year to date (YTD) performance is -1.37%.
US pharma major Bristol-Myers Squibb (NYSE:BMY) has presented new Phase III trial data of its combination therapy showing cure rates of up to 90% in certain groups of hepatitis C patients. Bristol-Myers Squibb Co (NYSE:BMY) weekly performance is -2.12%. On last trading day company shares ended up $48.83. Bristol-Myers Squibb Co (NYSE:BMY) distance from 50-day simple moving average (SMA50) is -6.76%. Analysts mean target price for the company is $55.12.
Leave a Reply